CareDx stock
CDNANASDAQCareDx, Inc, HealthcareISIN US14167L1035
59Score 59 out of 100, Neutral
Price and trend
82 / 100
Price history
+389% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 119% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 9.8% below its 52-week high. Largest decline in 12 years: 95% (January 2021 to October 2023).
Chart figures for advanced users
- SMA 50$65.78
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$36.42
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.51
- The lowest closing price of the last twelve months.
- Resistance$88.47
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CareDx, Inc belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $4.19B, is number 27 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $379.81M (up 13.8% year on year) and a loss of $21.35M.
- For fiscal 2026, analysts expect on average revenue of $524.89M (up 38.2%) and adjusted earnings per share of $1.78.
Show more
- MEQIRI Score 59 out of 100 (Neutral): rank 279 of 702 in Healthcare, median 53.
- Our model puts fair value at $37.40, with the price 113% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $250.48M, financial debt $29M.Stability 67
- High marginNet margin 25.9% over the last 12 months, Medical (Diagnostics & Research) median 6.7%.Profitability 75
- Growing faster than its industryRevenue up 14.6% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 77
Weaknesses
- Above fair valuePrice 113% above the fair value of $37.40.Valuation 23
- Volatile share priceVolatility 75% a year over the last 12 months.Stability 67
- DilutionShare count up 15% since 2020.Capital allocation 23
Its standout strengths are momentum and technical analysis, while valuation and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
- high price swings
What lowers it
- stable momentum
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $24.93 and expensive above $74.80 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $31.28, at 8.1% it would be $46.41.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38.9% on the twelve months before. Revenue has grown strongly since 2012, at around 25% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating −7%, net −6%. Last 12 months: net 26%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 29 Oct 2026EPS reported $0.70 (expected $0.25)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 48.7% since 15 Oct 2026.
- Earnings per share
- $1.78+48.7%
- Revenue
- $524.89M+6.0%
- Earnings per share
- $1.58+22.4%
- Revenue
- $572.48M+8.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +23.4%2026 revenue guidance raised to $490 million to $500 million (up 30% at the midpoint), adjusted EBITDA of $66 million to $78 million; includes the new specialty oncology business.
“Turning to guidance starting on slide 16, we are raising 2026 revenue guidance to $490 million to $500 million, representing a 30% increase year-over-year at the $495 million midpoint of the range and adjusted EBITDA from $66 million to $78 million or 15% of revenue at the $72 million midpoint of the range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $17.29M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Novack Jeffrey AdamSale
10 Nov 2026, Secretary and General Counsel
- Shares
- 4,096
- Price
- $81.13
- Value
- $332,291
- Kennedy KeithSale
5 Nov 2026, CFO & COO
- Shares
- 61,961
- Price
- $77.82
- Value
- $4.82M
- Bickerstaff GeorgeSale
5 Aug 2026, Board
- Shares
- 20,000
- Price
- $46.29
- Value
- $925,700
Show 13 more
- Novack Jeffrey AdamSale
5 Aug 2026, Secretary and General Counsel
- Shares
- 2,688
- Price
- $46.26
- Value
- $124,349
- Cournoyer ChristineSale
4 Aug 2026, Board
- Shares
- 16,000
- Price
- $46.94
- Value
- $750,973
- Goldberg MichaelSale
4 Aug 2026, Board
- Shares
- 44,700
- Price
- $47.06
- Value
- $2.1M
- Hanna John Walter JRSale
16 Jul 2026, President and CEO
- Shares
- 118,000
- Price
- $37.79
- Value
- $4.46M
- Valantine HannahSale
16 Jul 2026, Board
- Shares
- 28,779
- Price
- $36.15
- Value
- $1.04M
- Hanna John Walter JRSale
29 Jun 2026, President and CEO
- Shares
- 39,900
- Price
- $29.24
- Value
- $1.17M
- Hanna John Walter JRSale
26 Jun 2026, President and CEO
- Shares
- 100
- Price
- $29.00
- Value
- $2,900
- Hanna John Walter JRSale
15 Jun 2026, President and CEO
- Shares
- 17,683
- Price
- $24.03
- Value
- $424,877
- Valantine HannahSale
15 Jun 2026, Board
- Shares
- 12,103
- Price
- $23.11
- Value
- $279,728
- Hanna John Walter JRSale
11 Jun 2026, President and CEO
- Shares
- 21,998
- Price
- $24.02
- Value
- $528,443
- Hanna John Walter JRSale
4 Jun 2026, President and CEO
- Shares
- 4,835
- Price
- $24.00
- Value
- $116,045
- Torres Arthur ASale
15 May 2026, Board
- Shares
- 6,484
- Price
- $19.89
- Value
- $128,978
- Torres Arthur ASale
14 May 2026, Board
- Shares
- 4,086
- Price
- $20.97
- Value
- $85,698
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CareDx
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- GRAILGRAL $5.46B43
- DiaSorinDIA.MI $5.3B67
- BillionToOneBLLN $5.29B64
- Sotera HealthSHC $4.65B54
- Vimian GroupVIMIAN.ST $2.23B58
- NeoGenomicsNEO $2.15B39
- VeracyteVCYT $1.99B53
- PersonalisPSNL $1.72B41
ETFs that hold CareDx
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.86% | 0.50% | €127.64M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.35% | 0.49% | €318.64M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.38% | 0.30% | €185.82M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 0.36% | 0.40% | €1.5B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.14% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.14% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.13% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.13% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Jul 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.